Novartis has exercised its option to acquire all outstanding capital stock of IFM Due, a subsidiary company of IFM developing small molecules that inhibit the cGAS-STING pathway. The company entered into an option and collaboration agreement with Novartis in September 2019 whereby Novartis fully financed IFM Due’s research and development costs for the cGAS-STING program in exchange for the option to acquire IFM Due. Under the terms of the option exercise, IFM received $90 million upfront ...